TATM 2003;5(5 Suppl):15-19 In 1988, researchers described the successful outcome of an elective knee-joint surgical procedure during which hemostasis was secured in a hemophilia A patient with inhibitors by means of a new drug, recombinant activated factor VII (rFVIIa).Over the next 15 years, numerous published reports on the clinical management of hemophilia patients with inhibitors using rFVIIa have appeared. In this review, the authors summarize some of the major published works on rFVIIa and present surgical experiences from a single hemophilia treatment center.